Literature DB >> 20075940

Granzymes in cancer and immunity.

S P Cullen1, M Brunet, S J Martin.   

Abstract

Cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells are indispensable factors in the body's ongoing defence against viral infection and tumor development. CTL/NK cells recognize and kill infected or aberrant target cells by two major pathways: either through introduction of a battery of proteases - called granzymes - to the target cell cytosol, or through TNF superfamily-dependent killing. During granzyme-dependent killing, target cell death is quick and efficient and is mediated by multiple granzymes, acting via redundant cell death pathways. Although granzyme-mediated cell death has been intensively studied, recent work has also hinted at an alternative, proinflammatory role for these enzymes. Thus, in addition to their well-established role as intracellular effectors of target cell death, recent data suggest that granzymes may have an extracellular role in the propagation of immune signals. In this study, we discuss the role of granzymes as central factors in antitumor immunity, as well possible roles for these proteases as instigators of inflammation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20075940     DOI: 10.1038/cdd.2009.206

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  117 in total

1.  Chronic shift-lag alters the circadian clock of NK cells and promotes lung cancer growth in rats.

Authors:  Ryan W Logan; Changqing Zhang; Sengottuvelan Murugan; Stephanie O'Connell; Dale Levitt; Alan M Rosenwasser; Dipak K Sarkar
Journal:  J Immunol       Date:  2012-02-03       Impact factor: 5.422

2.  Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy.

Authors:  Matthew P Morrow; Kimberly A Kraynyak; Cornelia L Trimble; Mark L Bagarazzi; Albert J Sylvester; Michael Dallas; Dawson Knoblock; Jean D Boyer; Jian Yan; Russell Vang; Amir S Khan; Laurent Humeau; Niranjan Y Sardesai; J Joseph Kim; Stanley Plotkin; David B Weiner
Journal:  Clin Cancer Res       Date:  2017-10-30       Impact factor: 12.531

Review 3.  Aiming to immune elimination of ovarian cancer stem cells.

Authors:  Jiabo Di; Tjitske Duiveman-de Boer; Carl G Figdor; Ruurd Torensma
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

4.  Global expression profiling of peripheral Qa-1-restricted CD8αα+TCRαβ+ regulatory T cells reveals innate-like features: implications for immune-regulatory repertoire.

Authors:  Shaohsuan S Fanchiang; Radu Cojocaru; Mohammad Othman; Ritu Khanna; Matthew J Brooks; Trevor Smith; Xiaolei Tang; Igor Maricic; Anand Swaroop; Vipin Kumar
Journal:  Hum Immunol       Date:  2011-08-17       Impact factor: 2.850

Review 5.  Intestinal inflammation and colorectal cancer: a double-edged sword?

Authors:  Angelamaria Rizzo; Francesco Pallone; Giovanni Monteleone; Massimo Claudio Fantini
Journal:  World J Gastroenterol       Date:  2011-07-14       Impact factor: 5.742

6.  Expression patterns of immune genes in long-term cultured dental stem cells.

Authors:  Pukana Jayaraman; Vijayendran Govindasamy; Nareshwaran Gnanasegaran; Wijenthiran Kunasekaran; Punitha Vasanthan; Sabri Musa; Noor Hayaty Abu Kasim
Journal:  Clin Oral Investig       Date:  2015-06-06       Impact factor: 3.573

7.  Cytotoxic T Lymphocytes (CTLs) and Kidney Transplantation: An Overview.

Authors:  Federica Rascio; Paola Pontrelli; Giuseppe Grandaliano
Journal:  Methods Mol Biol       Date:  2021

8.  Use of antigen-primed dendritic cells for inducing antitumor immune responses in vitro in patients with non-small cell lung cancer.

Authors:  Irina Obleukhova; Nataliya Kiryishina; Svetlana Falaleeva; Julia Lopatnikova; Vasiliy Kurilin; Vadim Kozlov; Aleksander Vitsin; Andrey Cherkasov; Ekaterina Kulikova; Sergey Sennikov
Journal:  Oncol Lett       Date:  2017-11-14       Impact factor: 2.967

9.  TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.

Authors:  Hung C Tran; Zesheng Wan; Michael A Sheard; Jianping Sun; Jeremy R Jackson; Jemily Malvar; Yibing Xu; Larry Wang; Richard Sposto; Eugene S Kim; Shahab Asgharzadeh; Robert C Seeger
Journal:  Clin Cancer Res       Date:  2016-10-10       Impact factor: 12.531

10.  Heterodimeric Fc-fused IL12 shows potent antitumor activity by generating memory CD8+ T cells.

Authors:  Keunok Jung; Ji-Hee Ha; Jung-Eun Kim; Jeong-Ah Kim; Ye-Jin Kim; Chul-Ho Kim; Yong-Sung Kim
Journal:  Oncoimmunology       Date:  2018-03-06       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.